PDF herunterladen
CC BY-NC-ND 4.0 · Exp Clin Endocrinol Diabetes 2022; 130(06): 358-367
DOI: 10.1055/a-1608-0345
Article

Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients

Lijun Gao‡
1   Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
Hong Huang‡
1   Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
Lu Zhang‡
1   Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
Ningjing Zhang
1   Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
Yuzhe Fu
1   Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
Dalong Zhu
1   Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
Yan Bi 
1   Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
Wenhuan Feng 
1   Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
› Institutsangaben Funding This study was supported by grants from the National Natural Science Foundation of China (81970704, 81970689, 81900787, 81800752, and 81800719), National Key Research and Development Program of China (2016YFC1304804 and 2017YFC1309605), Jiangsu Provincial Key Medical Discipline (ZDXKB2016012), Key Project of Nanjing Clinical Medical Science, Key Research and Development Program of Jiangsu Province of China (BE2015604 and BE2016606), Medical and Health Research Projects of Nanjing in Jiangsu Province of China (YKK18067), Project of Standardised Diagnosis and Treatment of Key Diseases in Jiangsu Province of China (2015604), and Natural Science Foundation of Jiangsu Province of China (BK20201115). Drum Tower Hospital (affiliated with Nanjing University Medical School, China) provided sponsorship for article processing charges.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Purpose We compared the efficacy and safety of beinaglutide, a glucagon-like peptide-1 (GLP-1) analogue with metformin in lowering the bodyweight of patients who were overweight/obese and non-diabetic.

Patients and Methods Seventy-eight non-diabetic patients were randomly selected and beinaglutide or metformin was administered for 12 weeks. The primary endpoints were changes in body weight and the proportions of patients who lost≥5 and≥10% of their baseline body weights.

Results A total of 64 patients completed the study; patients in the beinaglutide group exhibited more bodyweight loss than those in the metformin group [(9.5±0.8%; 9.1±0.9 kg) and (5.1±0.9%; 4.5±0.8 kg), respectively, corresponding to a difference of approximately 4.5 kg (95% confidence interval, 2.2–6.9 kg; P<0.01)]. In the beinaglutide group, 90.6 and 40.6% of the patients lost≥5 and≥10% of their body weight, respectively, whereas, in the metformin group, these rates were 46.9 and 12.5%, respectively (P<0.01 and P<0.05). Weight loss following beinaglutide treatment mainly resulted from the loss of fat mass. Compared to metformin, beinaglutide induced a greater decrease in the body mass index, weight circumference, percent body fat, and body fat mass (total, trunk, limb, android, and gynoid). Additionally, beinaglutide decreased serum insulin levels and ameliorated insulin resistance.

Conclusions Beinaglutide is more efficient than metformin at reducing weight and fat mass in patients who are overweight/obese and non-diabetic. Beinaglutide may be a useful therapeutic option for overweight/obesity control in the Chinese population.

Key words

Glucagon-like peptide-1 receptor agonist - Biguanides - Weight loss ratio - Body composition

Supplementary Material



Publikationsverlauf

Eingereicht: 02. März 2021
Eingereicht: 27. Juli 2021

Angenommen: 10. August 2021

Artikel online veröffentlicht:
02. Dezember 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 American Diabetes A Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2020. Diabetes Care 2020; 43: S89-S97
    CrossrefPubMedGoogle Scholar
  • 2 Mertens IL, Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obesity (Silver Spring, Md.) 2000; 8: 270-278
    PubMedGoogle Scholar
  • 3 Warkentin LM, Das D, Majumdar SR. et al. The effect of weight loss on health-related quality of life: systematic review and meta-analysis of randomized trials. Obesity Rev 2014; 15: 169-182
    CrossrefPubMedGoogle Scholar
  • 4 Ma C, Avenell A, Bolland M. et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. Br Med J 2017; 359: j4849
    CrossrefPubMedGoogle Scholar
  • 5 Bray GA, Fruhbeck G, Ryan DH. et al. Management of obesity. Lancet 2016; 387: 1947-1956
    CrossrefPubMedGoogle Scholar
  • 6 Dombrowski SU, Knittle K, Avenell A. et al. Long term maintenance of weight loss with non-surgical interventions in obese adults: Systematic review and meta-analyses of randomised controlled trials. Br Med J 2014; 348: g2646
    CrossrefPubMedGoogle Scholar
  • 7 Pi-Sunyer X, Astrup A, Fujioka K. et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11-22
    CrossrefPubMedGoogle Scholar
  • 8 van Bloemendaal L, Ten Kulve JS, la Fleur SE. et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 2014; 221: T1-T16
    CrossrefPubMedGoogle Scholar
  • 9 Klonoff DC, Buse JB, Nielsen LL. et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275-286
    CrossrefPubMedGoogle Scholar
  • 10 Vilsboll T, Christensen M, Junker AE. et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Br Med J 2012; 344: d7771-d7771
    CrossrefPubMedGoogle Scholar
  • 11 Flint A, Raben A, Ersboll AK. et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001; 25: 781-792
    CrossrefPubMedGoogle Scholar
  • 12 Society CD. Chinese guideline for the prevention and treatment of type 2 diabetes mellitus (2020 edition). Chin J Endo Metab 2021; 37: 311-398
    PubMedGoogle Scholar
  • 13 Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-742
    CrossrefPubMedGoogle Scholar
  • 14 Application Manual for Benalutide Injection (Yishengtai). Approval Number: S20160007, Shanghai Renhui Bio-Pharmaceutical Co., Ltd.
    PubMed
  • 15 Zhang YL, Zhou C, Li XF. et al. Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: A 3–month, multicentre, observational, retrospective, open-label study. Obes Sci Pract 2019; 5: 366-375
    CrossrefPubMedGoogle Scholar
  • 16 American Diabetes A Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care 2018; 41: S73-s85
    CrossrefPubMedGoogle Scholar
  • 17 Desilets AR, Dhakal-Karki S, Dunican KC. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother 2008; 42: 817-826
    CrossrefPubMedGoogle Scholar
  • 18 Zhou J, Massey S, Story D. et al. Metformin: an old drug with new applications. Int J Mol Sci 2018; 19: 2863
    CrossrefPubMedGoogle Scholar
  • 19 Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes 2013; 121: 27-31
    PubMedGoogle Scholar
  • 20 Hui F, Zhang Y, Ren T. et al. Role of metformin in overweight and obese people without diabetes: A systematic review and network meta-analysis. Eur J Clin Pharmacol 2019; 75: 437-450
    CrossrefPubMedGoogle Scholar
  • 21 Guideline for primary care of obesity:practice version. 2019; Chin J Gen Pract 2020: 102-103
    PubMedGoogle Scholar
  • 22 Domecq JP, Prutsky G, Leppin A. et al. Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015; 100: 363-370
    CrossrefPubMedGoogle Scholar
  • 23 Jensterle M, Kravos NA, Goričar K. et al. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord 2017; 17: 5
    CrossrefPubMedGoogle Scholar
  • 24 Liu X, Zhang Y, Zheng S. et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol 2017; 87: 767-774
    CrossrefPubMedGoogle Scholar
  • 25 O'Neil PM, Birkenfeld AL, McGowan B. et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018; 392: 637-649
    CrossrefPubMedGoogle Scholar
  • 26 Apovian CM, Aronne LJ, Bessesen DH. et al. Pharmacological management of obesity: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100: 342-362
    CrossrefPubMedGoogle Scholar
  • 27 Feng WH, Bi Y, Li P. et al. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial. J Diabetes Investig 2019; 10: 399-407
    CrossrefPubMedGoogle Scholar
  • 28 Larsen JR, Vedtofte L, Jakobsen MSL. et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: A randomized clinical trial. JAMA Psychiatry 2017; 74: 719-728
    CrossrefPubMedGoogle Scholar
  • 29 Jendle J, Nauck MA, Matthews DR. et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009; 11: 1163-1172
    CrossrefPubMedGoogle Scholar
  • 30 Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018; 27: 740-756
    CrossrefPubMedGoogle Scholar
  • 31 Feng W, Gao C, Bi Y. et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. J Diabetes 2017; 9: 800-809
    CrossrefPubMedGoogle Scholar
  • 32 Armstrong MJ, Gaunt P, Aithal GP. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: 679-690
    CrossrefPubMedGoogle Scholar
  • 33 Doyle ME, Egan JM. Mechanisms of action of GLP-1 in the pancreas. Pharmacol Ther 2007; 113: 546-593
    CrossrefPubMedGoogle Scholar
  • 34 Tsushima Y, Nishizawa H, Tochino Y. et al. Uric acid secretion from adipose tissue and its increase in obesity. J Biol Chem 2013; 288: 27138-27149
    CrossrefPubMedGoogle Scholar
  • 35 Piaggi P, Thearle MS, Bogardus C. et al. Lower energy expenditure predicts long-term increases in weight and fat mass. J Clin Endocrinol Metab 2013; 98: E703-E707
    CrossrefPubMedGoogle Scholar
  • 36 Palmer BF, Clegg DJ. Strategies to counter weight loss-induced reductions in metabolic rate. Curr Sport Med Rep 2019; 18: 258-265
    CrossrefPubMedGoogle Scholar